STRATA ADVISES LGC ON THE ACQUISITION OF KBIOSCIENCE
Strata advises LGC on the acquisition of KBioscience to create a market leader in genomic services and solutions
Strata Partners is pleased to announce that it advised LGC on the combination of LGC`s Genomics division with KBioscience to create a market-leading genomic services and solutions provider. The combination was enabled through the acquisition by LGC Limited (“LGC”) of KBiosciences Limited (“KBioscience”) on 1 July. The founders of KBioscience remain partners and significant shareholders in the enlarged business alongside LGC.
The acquisition of KBioscience, with its unique expertise in genotyping services, chemistries and related products, extends and complements LGC`s cutting-edge genomic services and products, supplied through its LGC Genomics division.
The combining of LGC’s and KBioscience’s activities furthers LGC Genomics’ aim to become Europe’s leading provider of genomic services and related products. Both KBioscience and LGC have established national and international reputations.
Formed in 2002, KBioscience has almost 10 years’ experience developing and optimising genotyping assays using the company’s patented fluorescence-based competitive allelespecific PCR (polymerase chain reaction) technique, KASP. KBioscience’s scientists have contributed significantly to the development of new, genotyping technologies making affordable projects accessible to a broad range of customers independent of project size.
LGC’s products and services in DNA sequencing and extraction are fully complementary to the systems and services developed by KBioscience. The combined business benefits from a significant shared customer base and will use the knowledge and skills of the LGC and KBioscience teams to deliver a comprehensive set of genomics services, products and future innovations.
Mark Sargeant, Partner, commented: “We were delighted to assist LGC with this important transaction which creates a market leader in genomic services and solutions. The transaction builds on our impressive track record in laboratory testing and life science services and confirms our position as the UK`s leading M&A advisory boutique in these fields”.